Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Project Oncology®
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Steve Jackson, PharmD; Paolo F. Caimi, MD
- Steve Jackson, PharmD
- Paolo F. Caimi, MD
- Narendranath Epperla, MD, MS
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
Project Oncology®
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
John Cho, MD, PhD, FRCPC
- John Cho, MD, PhD, FRCPC
From Durability to Discovery: Advances in ALK+ mNSCLC Treatment
From Durability to Discovery: Advances in ALK+ mNSCLC Treatment
Project Oncology®
From Durability to Discovery: Advances in ALK+ mNSCLC Treatment
Angel Qin, MD
- Angel Qin, MD
How Novel Strategies Could Push ALK+ mNSCLC Care Forward
How Novel Strategies Could Push ALK+ mNSCLC Care Forward
Project Oncology®
How Novel Strategies Could Push ALK+ mNSCLC Care Forward
Angel Qin, MD
- Angel Qin, MD
Investigating Unanswered Questions in ALK+ mNSCLC Care
Investigating Unanswered Questions in ALK+ mNSCLC Care
Project Oncology®
Investigating Unanswered Questions in ALK+ mNSCLC Care
Alice T. Shaw, MD, PhD
- Alice T. Shaw, MD, PhD
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Project Oncology®
Comparing CAR T-Cell Therapies for R/R Multiple Myeloma
Charles Turck, PharmD, BCPS, BCCCP; Krina Patel, MD, MSc
- Charles Turck, PharmD, BCPS, BCCCP
- Krina Patel, MD, MSc
CAR T-Cell vs Bispecific Therapies for R/R Multiple Myeloma: How They Compare
CAR T-Cell vs Bispecific Therapies for R/R Multiple Myeloma: How They Compare
Project Oncology®
CAR T-Cell vs Bispecific Therapies for R/R Multiple Myeloma: How They Compare
Charles Turck, PharmD, BCPS, BCCCP; Krina Patel, MD, MSc
- Charles Turck, PharmD, BCPS, BCCCP
- Krina Patel, MD, MSc
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Project Oncology®
Managing MAPK Inhibitor Adverse Events in Pediatric Low-Grade Gliomas
Alexandria May, PharmD, BCPS; Shannon Raber, MS, CPNP, RN
- Alexandria May, PharmD, BCPS
- Shannon Raber, MS, CPNP, RN
- Bridget Archambault, MSN, CPNP

Medical News

Medical News
Roginolisib Trial Shows PI3Kδ Target Engagement in Uveal Melanoma
10/13/2026
Read more
Medical News
CT Body Composition Radiomics Improves NSCLC Survival Prediction
10/12/2026
Read more
Medical News
KRAS/TP53 Co-Mutation Linked to Better ICI Outcomes in LUAD
10/12/2026
Read more
Medical News
Checkpoint Inhibitor Rheumatic Toxicity in ERIN Registry
10/12/2026
Read more

CME/CE

CME/CE In-Person & Virtual Event
Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026
Scottsdale, Arizona
1.00 credit
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
0.75 program credits
- Natalie S. Callander, MD
0.75 program credits
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
MinuteCE®
Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
Saad Z. Usmani, MD, MBA; Natalie S. Callander, MD
0.75 program credits
- Saad Z. Usmani, MD, MBA
- Natalie S. Callander, MD
0.75 program credits

Clinical Practice

Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Clinician's Roundtable
Personalized CRC Screening: Applying Real-World Evidence to Test Selection
Brian P. McDonough, MD, FAAFP; David A. Johnson, MD, FACG, FACP
- Brian P. McDonough, MD, FAAFP
- David A. Johnson, MD, FACG, FACP
Molecular Testing in Advanced Non-Small Cell Lung Cancer
Molecular Testing in Advanced Non-Small Cell Lung Cancer
On the Frontlines of Non-Small Cell Lung Cancer
Molecular Testing in Advanced Non-Small Cell Lung Cancer
Alexandria May, PharmD, BCPS; Timothy F. Burns, MD, PhD
- Alexandria May, PharmD, BCPS
- Timothy F. Burns, MD, PhD
Guiding mNSCLC Treatment After ALK-TKI Progression
Guiding mNSCLC Treatment After ALK-TKI Progression
Project Oncology®
Guiding mNSCLC Treatment After ALK-TKI Progression
Alice T. Shaw, MD, PhD
- Alice T. Shaw, MD, PhD
Patterns of Progression and Resistance in ALK+ mNSCLC
Patterns of Progression and Resistance in ALK+ mNSCLC
Project Oncology®
Patterns of Progression and Resistance in ALK+ mNSCLC
Alice T. Shaw, MD, PhD
- Alice T. Shaw, MD, PhD

Programs

Advancing Metastatic Breast Cancer Research Through Philanthropy
Advancing Metastatic Breast Cancer Research Through Philanthropy
On the Frontlines of Metastatic Breast Cancer
Advancing Metastatic Breast Cancer Research Through Philanthropy
Steve Jackson, PharmD; Ted Giovanis, FHFMA, MBA
- Steve Jackson, PharmD
- Ted Giovanis, FHFMA, MBA
Interpreting Oral SERD Trial Data in Metastatic Breast Cancer
Interpreting Oral SERD Trial Data in Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Interpreting Oral SERD Trial Data in Metastatic Breast Cancer
Alexandria May, PharmD, BCPS; Donald McDonnell, PhD
- Alexandria May, PharmD, BCPS
- Donald McDonnell, PhD
- Neil M. Iyengar, MD
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Project Oncology®
Emerging Biomarker Research for NSCLC Antibody-Drug Conjugates
Christine Bestvina, MD
- Christine Bestvina, MD
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Project Oncology®
Antibody-Drug Conjugates for NSCLC: How They Work and Who’s a Candidate
Laura Alder, MD
- Laura Alder, MD